Equities Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of ($0.14) for the quarter, up from their previous forecast of ($0.16). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q3 2024 earnings at ($0.10) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.51) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at $0.43 EPS.

Several other research firms have also issued reports on BCRX. JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $5.10 on Thursday. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.96. The company has a 50-day simple moving average of $4.89 and a two-hundred day simple moving average of $5.45. The firm has a market capitalization of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analysts’ expectations of $85.62 million. During the same quarter last year, the business earned ($0.28) earnings per share. The business’s quarterly revenue was up 34.9% on a year-over-year basis.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of BCRX. Bank of New York Mellon Corp boosted its holdings in shares of BioCryst Pharmaceuticals by 1.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 767,571 shares of the biotechnology company’s stock valued at $5,434,000 after acquiring an additional 8,087 shares during the last quarter. Arete Wealth Advisors LLC raised its position in shares of BioCryst Pharmaceuticals by 64.7% in the third quarter. Arete Wealth Advisors LLC now owns 23,300 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 9,150 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 2,388 shares during the last quarter. Fifth Third Bancorp raised its position in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,500 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in BioCryst Pharmaceuticals by 6.1% during the third quarter. Panagora Asset Management Inc. now owns 727,480 shares of the biotechnology company’s stock worth $5,151,000 after purchasing an additional 41,971 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.